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Abstract 
Review on Ataxia telangiectasia, with data on 
clinics, and the gene involved. 
Keywords 
Review on Ataxia telangiectasia, with data on 
clinics, and the gene involved. 
Identity 
Other names 
Louis-Bar syndrome 
Note 
See also, in Deep Insight section: Ataxia-
Telangiectasia and variants. 
Inheritance 
Autosomal recessive disease. Genome instability 
syndrome found worldwide with incidence of .0.5. 
to 2.5/105 newborns in different human populations. 
A founder effect is found in some isolated 
population. Heterozygotes are estimated to be 1% 
of the general population. The clinical phenotype of 
A-T ranges from severe to milder variants of the 
disease, but is usually portrayed by its classical, 
severe form (Perlman SL et al., 2012; Lavin MF, 
2008; Crawford TO, 1998; Chun HH et al., 2004; 
Nissenkorn A et al., 2016). However, awareness is 
growing of the broad clinical variability associated 
with the causative mutations (Taylor AM et al., 
2015). 
The primary cause of all variants of the disease is 
mutations in the autosomal gene ATM (A-T, 
mutated) at 11q22-23 (Gatti RA et al., 1988; 
Savitsky K et al., 1995a), which encodes the ATM 
protein (Savitsky K et al., 1995b; Ziv Y et al., 
1997) a multi-functional protein kinase (Shiloh Y et 
al., 2013; Shiloh Y, 2014; Guleria A et al., 2016; 
Ditch S et al., 2012). 
Clinics 
Ataxia telangiectasia is a chromosome instability 
syndrome (Perlman SL et al., 2012; Lavin MF, 
2008; Crawford TO, 1998; Chun HH et al., 2004; 
Taylor AM et al., 1982; Taylor AM et al., 2015; 
Taylor AM, 1978; Butterworth SV et al., 1986; 
Kennaugh AA et al., 1986) with cerebellar 
degeneration, immunodeficiency, and an increased 
risk of cancers; A-T cells are defective in 
recognizing double-strand DNA damage to signal 
for repair.  
The cellular phenotype of A-T represents genome 
instability, deficient DNA damage response (DDR), 
and elevated oxidative stress, in addition to a 
premature senescence component (Shiloh Y et al., 
1982). A-T patients show a striking sensitivity to 
the cytotoxic effect of ionizing radiation (Gotoff SP 
et al., 1967; Morgan JL et al., 1968). Cells from A-
T patients exhibit marked chromosomal instability 
and sensitivity to ionizing radiations and 
radiomimetic chemicals (Taylor AM, 1978; Taylor 
AM et al., 1975; Taylor AM et al., 1979; Shiloh Y 
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et al., 1982; Shiloh Y et al., 1983; Djuzenova CS et 
al., 1999). This acute sensitivity results from a 
profound defect in the cellular response to DNA 
double-strand breaks (DSBs), whose chief 
mobilizer is the ATM protein. It is important to 
note, however, that A-T cells are also moderately 
sensitive to a wide array of other DNA damaging 
agents suggesting that these cells cope less 
efficiently with many other DNA lesions besides 
DSBs. 
Phenotype and clinics 
Onset of the disease is often noted during the 
second year of life: there is progressive cerebellar 
ataxia (initially truncal, with further peripheral 
extension); ataxia is a constant feature in this 
disease; oculomotor apraxia, dysarthria, and 
dystonia; leading to muscular atrophia.  
Cerebellar ataxia. The prominent symptom of 
classical A-T is progressive cerebellar ataxia that 
develops into a general motor dysfunction, 
eventually confining most patients to a wheelchair 
around the end of their first decade  (Crawford TO, 
1998; Chun HH et al., 2004; Nissenkorn A et al., 
2016; Boder E et al., 1958; Sedgwick RP et al., 
1960; Boder E, 1985; Crawford TO et al., 2000; 
Gatti RA, 1995; Verhagen MM et al., 2012). The 
main underlying pathology appears to be 
progressive cerebellar cortical degeneration that 
primarily affects Purkinje and granule neurons, but 
also basket cells (Vinters HV et al., 1985; Gatti RA 
et al., 1985). 
 Impairment of the extrapyramidal movement 
system is common in A-T, as are oculomotor 
abnormalities such as apraxia, strabismus and 
nystagmus. Swallowing and articulation of speech 
are often abnormal, and facial expression is limited. 
Dysfunctional swallowing is often associated with a 
general nutritional problem as well as clinically 
unapparent aspiration, which is thought to play a 
role in the increasing frequency of lower respiratory 
tract infections in many patients (Lefton-Greif MA 
et al., 2000; Bhatt JM et al., 2015). An absence of 
deep reflexes and peripheral neuropathy are 
common in A-T, but usually develop relatively later 
than other neurological impairments (Nissenkorn A 
et al., 2016). 
 Oculocutaneous telangiectasia (dilated blood 
vessels) appear at various ages, usually in the eyes 
(conjunctiva) and sometimes on the ears and facial 
skin exposed to sunlight, (Perlman SL et al., 2012; 
Greenberger S et al., 2013). Finally, telangiectasia 
appear in the brain and other internal organs of 
young adults with A-T, a peculiar finding seen in 
people without A-T only as a late effect of 
treatment with ionizing radiation for cancer therapy 
(Lin DD et al., 2014). 
 Combined Immunodeficiency (in 70 %) is 
another hallmark of A-T. Typically, IgA, IgE and 
various IgG subclasses are reduced; a diminished 
lymphocyte count is common, affecting B and T 
but not natural killer cells, and many have impaired 
antibody responses to vaccines (Gatti RA, 1995),  
(Nowak-Wegrzyn A et al., 2004; Gatti RA et al., 
1982; Weaver M et al., 1985; Härtlova A et al., 
2015). The thymus is typically vestigial, as are the 
gonads. 
Growth/Puberty. Many children with A-T grow at 
a diminished rate, and puberty is often delayed; this 
growth retardation was suggested to result from a 
primary endocrine defect (Ehlayel M et al., 2014; 
Voss S et al., 2014; Pommerening H et al., 2015; 
Ehlayel M et al., 2014), or a primary growth defect 
(Nissenkorn A et al., 2016), but is probably also a 
function of swallowing problems making eating an 
inefficient and exhausting task. 
 Dyslipidemia and diabetes. There was also an 
increased incidence of dyslipidemia (10/52 = 19%) 
and diabetes (2/52 = 4%; Nissenkorn A et al., 
2016). These abnormalities together with elevated 
levels of C-reactive protein suggest a diagnosis of 
metabolic syndrome in a substantial number of 
young A-T patients. Insulin-resistant diabetes is an 
important endocrine abnormality in some patients 
(Nissenkorn A et al., 2016; Schalch DS et al., 1970; 
Morrell D et al., 1986; Blevins LS Jr et al., 1996). 
 Osteoporosis is common because of a lack of 
weight bearing, nutritional deficiencies, and early 
gonadal failure in females. Incapacitating fatigue 
affects a majority of A-T patients over the age of 
30. The etiology of this problem is likely to be 
multifactorial, with contributions from the extra 
effort required to function with neurodegeneration, 
and central nervous system effects of elevated 
levels of pro-inflammatory cytokines including IL-
6 and IL-8 (McGrath-Morrow SA et al., 2016) and 
chronic, elevated levels of Type I interferons 
(Härtlova A et al., 2015). 
 SenescenceA-T has recently emerged as a 
premature aging disease. The broad immune system 
defects in A-T have been regarded as a reflection of 
premature ageing of this system in these patients 
(Exley AR et al., 2011; Carney EF et al., 2012). 
Finding striking similarities between the immune 
system phenotypes of A-T patients and the elderly 
(Carney EF et al., 2012), it was concluded that the 
immune system of A-T patients is congenitally 
aged, and A-T could be viewed as a model of 
immune ageing (Exley AR et al., 2011). Similarly, 
the resemblance between ageing-associated decline 
of brain functionality and neurodegeneration 
associated with genome instability has recently 
been highlighted (Barzilai A et al., 2016). 
Adolescents and young adults with A-T exhibit an 
array of health problems that are typically not seen 
until late middle age or later. Among 53 A-T 
patients with mean age of 14.6 years (range 5.9 - 
26.1), 43% had elevated serum transaminases, 39% 
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of those patients had fatty liver detected by 
ultrasound, and 33% of the latter group developed 
steatohepatitis , fibrosis or cirrhosis (Weiss B et al., 
2016). Progeric features of skin include premature 
greying and thinning of hair, thinning of skin, and 
vitiligo (Reed WB et al., 1966). 
Neoplastic risk 
Another prominent clinical hallmark of A-T is 
cancer predisposition; risk of cancers is X 100, 
consisting mainly of T- cell malignancies (a 70-fold 
and 250-fold increased risks of leukemia of both B 
cell and T cell origin, and 250-fold increased risks 
of non-Hodgkin's lymphoma and Hodgkin's 
lymphoma), but not myeloid leukemia (Loeb DM et 
al., 2000; Murphy RC et al., 1999; Olsen JH et al., 
2001; Taylor AM et al., 1982). There is a striking 
incidence of gammopathy in A-T (Sadighi Akha 
AA et al., 1999), another abnormality that is rarely 
seen in people < 30 years old. 
The most common malignancies in A-T patients of 
all ages are of lymphocytic origin. However, among 
those from 18-40 years old with cancer, 11/21 
(52%) had cancers of solid organs (stomach, 
esophagus,liver,parotid gland, thyroid, skin,breast 
and lung) that are rarely seen in that age group 
among people without A-T (HM Lederman, L 
Chessa, unpublished observations). 
Cancer treatment is complicated by radiation- and 
chemo-sensitivity. 
Evolution 
Progressive cerebellar degeneration: patients are 
usually in a wheelchair by the age of ten. 
Prognosis 
Respiratory infection is the common cause of death, 
with cancer being the second most common. 
Survival is often into fourth decade today where 
optimal medical care is available. 
Cytogenetics 
Difficulty to grow cells with phytohemaglutinin: 
karyotypes should be performed with interleukine 2 
in 4 days cultures. 
Lymphocyte cultures from A-T patients often 
contain clonal translocations that mainly involve 
the loci of the T-cell receptor and immunoglobulin 
heavy-chain genes (Butterworth SV et al., 1986; 
Kennaugh AA et al., 1986; Taylor AM et al., 1986; 
Heppell A et al., 1988; Kojis TL et al., 1991), 
pointing to a defect in the maturation of these genes 
via V(D)J and class-switch recombination in the 
adaptive immune system. Such clones usually 
herald the onset of malignancy and expand as 
malignancy progresses. Cultured A-T cell strains 
exhibit elevated rates of chromosome end 
associations and reduced telomere length (Pandita 
TK et al., 1995; Smilenov LB et al., 1999; Wood 
LD et al., 2001; Metcalfe JA et al., 1996; Vaziri H, 
1997). A-T fibroblast strains exhibit similar growth 
properties to wild-type cells at early passage levels 
but senesce prematurely (Shiloh Y et al., 1982). 
Inborn conditions 
Spontaneous chromatid/chromosome breaks, 
triradials, quadriradials (less prominent 
phenomenon than in Fanconi anaemia); telomeric 
associations. 
The best diagnosis test is on the (pathognomonic) 
highly elevated level (10% of mitoses) of 
inv(7)(p14q35), t(14;14)(q11;q32), and other non 
clonal stable chromosome rearrangements 
involving 2p12, 7p14, 7q 35, 14q11, 14q32, and 
22q11 (illegitimate recombinations between 
immunoglobulin superfamilly genes Ig and TCR); 
normal level of those rearrangements are: 1/500 
(inv(14)), 1/200 (t(7;14)), 1/10 000 (inv(7)). 
Clonal rearrangements further occur in 10% of 
patients, but without manifestation of malignancy: 
t(14;14), inv(14), or t(X;14). 
Cytogenetics of cancer 
Clonal rearrangements in T-cell ALL and T-PLL 
(prolymphocytic leukaemia) in AT patients are 
complex, with the frequent involvement of 
t(14;14)(q11;q32)(q11;q32), or t(X;14)(q28;q11), 
implicating the genes TCL1 or MTCP1 
respectively, as is found in T-Pro Lymphocytic 
Leukemia in non-AT patients. 
Other findings 
High sensitivity to ionizing radiations and to 
radiomimetic drugs (diagnostic may in part be 
based on the hypersensitivity of AT lymphocytes to 
killing by gamma irradiation); cell irradiation does 
not inhibit S phase (DNA synthesis): this is quite 
pathognomonic of AT, and shows that G1 
checkpoint is deficient; there is a lack of  TP53, 
GADD45 and CDKN1A (P21) induction, and a fall 
in radiation-induced apoptosis; TP53 
phosphorylation at ser15 is deficient. 
 Telomeres.  The observation of accelerated 
telomere shortening and telomere fusions in 
peripheral blood lymphocytes (Metcalfe JA et al., 
1996) and cultured fibroblasts (Xia SJ et al., 1996; 
Smilenov LB et al., 1997) from A-T patients and 
cell lines expressing dominant-negative ATM 
fragments (Smilenov LB et al., 1997) exposed an 
important possible contributor to premature 
senescence of ATM-deficient cells. The wealth of 
information currently available on telomere 
maintenance and the role of the DDR in telomere 
dynamics (reviewed in (Webb CJ et al., 2013; 
Doksani Y et al., 2014; Arnoult N et al., 2015) has 
tightly linked ATM to telomere homeostasis and 
added an important component to the ageing aspect 
of A-T. 
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Sporadic (rows 1 and 2) and clonal (row 3) rearrangements in ataxia telangiectasia (R- banding). Row 1, from left to right: 
inv(7)(p14q35), t(7;7)(p14;q35), t(14;14)(q11;q32), inv(14)(q11q32); Row 2:, from left to right: t(7;14)(p14;q11), t(7;14)(q35;q11), 
t(7;14)(p14;q32), t(7;14)(q35;q32); Row 3, from left to right: inv(14)(q11;q32), t(X;14)(q28;q11) (note the late replicating X on the 
left ), t(14;14)(q11;q32) - Courtesy Alain Aurias (modified figure reprinted from Médecine/Sciences 1986; 2: 298-303., by 
permission of the publisher Masson). 
 
Lenthening of the cell cycle. 
Oxidative stress.  Increasing numbers of reports 
have described elevated readouts of oxidative stress 
in plasma of A-T patients (Reichenbach J et al., 
2002), in cultured A-T fibroblasts (Gatei M et al., 
2001; Lee SA et al., 2001) and lymphocytes 
(Ludwig LB et al., 2013), and in tissues and 
cultured cells from Atm-deficient mice (Barlow C 
et al., 1999; Kamsler A et al., 2001; Gage BM et 
al., 2001; Ziv S et al., 2005; Chen P et al., 2003; 
Reliene R et al., 2004; Reliene R et al., 2007; Liu N 
et al., 2005; McDonald CJ et al., 2011). Notably, 
the response of A-T fibroblast strains to induced 
oxidative stress was found defective (Yi M et al., 
1990; Ward AJ et al., 1994). These observations 
were later linked to the role of ATM in regulating 
cellular oxidative stress. 
Alpha fetoprotein/serum carcinoembryonic 
antigen Notable laboratory findings are elevation 
of serum alpha fetoprotein and serum 
carcinoembryonic antigen. Further aspects of A-T, 
which entail segmental premature ageing. 
Genes involved and 
proteins 
Gene 
ATM (ataxia telangiectasia mutated) 
Location 
11q22.3 
DNA/RNA 
Description 
66 exons spanning 184 kb of genomic DNA. 
Transcription 
Northern blot analysis shows two transcript: the 
first-one, TRIM37a of about 4.5-kb and the second-
one, TRIM37b of approximately 3.9 kb. 
Protein 
Description 
3056 amino acids; 350 kDa; contains a Pl 3-kinase-
like domain. 
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Localisation 
Mostly in the nucleus in replicating cells, cytoplasm 
in differentiating cells. 
Function 
Homeostatic protein kinase involved in many 
cellular circuits. A primary role in the DNA damage 
response. Activated vigorously by DNA double-
strand breaks and activates a broad network of 
responses. ATM initiates cell cycle checkpoints in 
response to double-strand DNA breaks by 
phosphorylating TP53, BRCA1, H2AFX ID: 
40783,  
 Double strand breaks. The most widely 
documented function of ATM, and the one 
associated with its most vigorous activation, is the 
mobilization of the complex signaling network that 
responds to DSBs in the DNA (Shiloh Y et al., 
2013; Cremona CA et al., 2014; Awasthi P et al., 
2016; Thompson LH, 2012; McKinnon PJ, 2012). 
DSBs are induced by exogenous DNA breaking 
agents or endogenous reactive oxygen species 
(Schieber M et al., 2014), and are an integral part of 
physiological processes including meiotic 
recombination (Borde V et al., 2013; Lange J et al., 
2011) and the rearrangement of antigen receptor 
genes in the adaptive immune system (Alt FW et 
al., 2013). DSBs are repaired via nonhomologous 
end-joining (NHEJ), or homologous recombination 
repair (HRR; Shibata A et al., 2014; Chapman JR et 
al., 2012; Jasin M et al., 2013; Radhakrishnan SK et 
al., 2014). Once ATM mobilizes the vast DDR 
network in response to a DSB (McKinnon PJ, 2012; 
Shiloh Y et al., 2013; Bhatti S et al., 2011), its 
protein kinase activity is rapidly enhanced. ATM 
subsequently phosphorylates key players in various 
arms of the DSB response network (Shiloh Y et al., 
2013; Bensimon A et al., 2010; Matsuoka S et al., 
2007; Mu JJ et al., 2007; Bensimon A et al., 2011), 
including other protein kinases that in turn 
phosphorylate still other targets (Bensimon A et al., 
2011). 
 Single-strand break repair and base excision 
repair. A broader, overarching role for ATM in 
maintaining genome stability was recently 
suggested in addition to mobilizing the DSB 
response (Shiloh Y, 2014). According to this 
conjecture, ATM supports other DNA repair 
pathways that respond to various genotoxic 
stresses, among them single-strand break repair 
(SSBR; Khoronenkova SV et al., 2015) and base 
excision repair (BER) - a cardinal pathway in 
dealing with the daily nuclear and mitochondrial 
DNA damage caused by endogenous agents 
(Wallace SS, 2014; Bauer NC et al., 2015). ATM's 
involvement in these processes is based on its 
ability to phosphorylate proteins that function in 
these pathways. 
This ongoing role of ATM is its routine function in 
the daily maintenance of genome stability, while its 
powerful role in the DSB response is reserved for 
when this harmful lesion interferes with the daily 
life of a cell. Thus, when ATM is missing, not only 
is there markedly reduced response to DSBs, the 
ongoing modulation of numerous pathways in 
response to occasional stresses becomes 
suboptimal. All of these lesions are part of the daily 
wear and tear on the genome that contributes to 
ageing.  
An additional role for ATM in genome dynamics 
was proposed following evidence that ATM is 
involved in shaping the epigenome in neurons by 
regulating the localization of the histone 
deacetylase 4 (HDAC4; Li J et al., 2012; Herrup K 
et al., 2013; Herrup K, 2013), targeting the EZH2 
component of the polycomb repressive complex 2 
(Li J et al., 2013), and regulating the levels of 5-
hydroxymethylcytosine in Purkinje cells (Jiang D et 
al., 2015). 
 Oxidative stress/Cellular homeostasis. 
 Cytoplasmic fraction of ATM. ATM's role in 
cellular homeostasis is further expanded by its 
cytoplasmic fraction. Specifically, cytoplasmic 
ATM was found to be associated with peroxisomes 
(Watters D et al., 1999; Tripathi DN et al., 2016; 
Zhang J et al., 2015) and mitochondria (Valentin-
Vega YA et al., 2012). In view of the evidence of 
increased oxidative stress in ATM-deficient cells, it 
has long been suspected that ATM senses and 
responds to oxidative stress (Gatei M et al., 2001; 
Rotman G et al., 1997; Rotman G et al., 1997; 
Barzilai A et al., 2002; Watters DJ, 2003; Takao N 
et al., 2000; Alexander A et al., 2010). This 
conjecture was validated by work from the Paull lab 
(Guo Z et al., 2010a), which identified an MRN-
independent mode of ATM activation, 
differentiating it from DSB-induced activation, 
stimulated by reactive oxygen species (ROS) and 
leading to ATM oxidation (Paull TT, 2015; Guo Z 
et al., 2010a; Guo Z et al., 2010b; Lee JH et al., 
2014). 
 Mitochondrial fraction of ATM. Still another 
arm of the ATM-mediated response to oxidative 
stress operates in the mitochondrial fraction of 
ATM. ATM is thus emerging also as a regulator of 
mitochondrial homeostasis. Evidence is 
accumulating of its involvement in mitochondrial 
function, mitophagy, and the integrity of 
mitochondrial DNA (Valentin-Vega YA et al., 
2012; Ambrose M et al., 2007; Eaton JS et al., 
2007; Fu X et al., 2008; Valentin-Vega YA et al., 
2012; D'Souza AD et al., 2013; Sharma NK et al., 
2014) and further work is needed to identify its 
substrates in mitochondria and the mechanistic 
aspects of its action in this arena. 
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 Links between ATM and the SASP (senescence-
associated secretory phenotype). Several 
laboratories recently described direct links between 
ATM and the SASP - a cardinal feature of cell 
senescence. Work from the Gamble lab (Chen H et 
al., 2015) showed that the histone variant 
macroH2A.1 is required for full transcriptional 
activation of SASP-promoting genes, driving a 
positive feedback loop that enhances cell 
senescence. This response is countered by a 
negative feedback loop that involves ATM 
activation by endoplasmic reticulum stress, elevated 
ROS levels or DNA damage. ATM's activity is 
required for the removal of macroH2A.1 from sites 
of SASP genes, thus leading to SASP gene 
repression. 
 Insulin response and lipoprotein metabolism. 
 IGF-1 receptor. Another pathway by which ATM 
may impact on cellular senescence is the 
dependence of IGF1R (IGF-1 receptor) expression 
on ATM (Peretz S et al., 2001; Goetz EM et al., 
2011; Ching JK et al., 2013). 
 Beta-adrenergic receptor. Another series of 
observations assigned ATM a protective role in 
cardiac myocyte apoptosis stimulated by β-
adrenergic receptor and myocardial remodeling. 
Mutations 
Germinal 
Various types of mutations, dispersed throughout 
the gene, and therefore most patients are compound 
heterozygotes; however, most mutations appear to 
inactivate the ATM protein by truncation, large 
deletions, or annulation of initiation or termination. 
Missense mutations have been described in breast 
cancer patients, but do not seem to contribute to 
ataxia-telangiectasia.  
Patients with the severe form of A-T are 
homozygous or compound heterozygous for null 
ATM alleles. The corresponding mutations usually 
lead to truncation of the ATM protein and 
subsequently to its loss due to instability of the 
truncated derivatives; a smaller portion of the 
mutations create amino acid substitutions that 
abolish ATM's catalytic activity (Taylor AM et al., 
2015; Gilad S et al., 1996; Sandoval N et al., 1999; 
Barone G et al., 2009) (see also 
http://chromium.liacs.nl/LOVD2/home.php?select_
db=ATM). 
Careful inspection of the neurological symptoms of 
A-T patients reveals variability in their age of onset 
and rate of progression among patients with 
different combinations of null ATM alleles (Taylor 
AM et al., 2015; Crawford TO et al., 2000; 
Alterman N et al., 2007). Thus, despite the identical 
outcome in terms of ATM function, additional 
genes may affect the most cardinal symptom of A-
T. Other, milder types of ATM mutations further 
extend this variability, and account for forms of the 
disease with extremely variable severity and age of 
onset of symptoms.  
The corresponding ATM genotypes are 
combinations of hypomorphic alleles or 
combinations of null and hypomorphic ones. Many 
of the latter are leaky splicing mutations and others 
are missense mutations, eventually yielding low 
amounts of active ATM (Taylor AM et al., 2015; 
Alterman N et al., 2007; Soresina A et al., 2008; 
Verhagen MM et al., 2009; Silvestri G et al., 2010; 
Saunders-Pullman R et al., 2012; Verhagen MM et 
al., 2012; Worth PF et al., 2013; Claes K et al., 
2013; Méneret A et al., 2014; Nakamura K et al., 
2014; Gilad S et al., 1998). 
To be noted 
Heterozygote cancer risk: the relative risk of breast 
cancer in A-T heterozygote women has been 
estimated through epidemiological studies to be 3.9 
(CI 2.1-7.1), and through haplotype analysis to be 
3.32 (CI 1.75-6.38); since the A-T heterozygote 
frequency is about 1 %, 2-4 % of breast cancer 
cases may be due to ATM heterozygosity; the risk 
of other types of cancer in A-T heterozygotes is 
low. 
The A-T variant Nijmegen breakage syndrome does 
not involve the same gene, but, instead, NBN or 
RAD50, involved in the MRE11/RAD50/NBN 
double-strand break repair complex. 
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